Table 1 Characteristics of the selected randomized controlled trials.
Author, year | Corticosteroid | Intervention group (ultrasound-guided injection) | Control group (landmark-guided injection) | Outcome measures | Follow-up duration (weeks) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Plane of approach | n (hands) | Mean age (SD) | Mean symptom duration (weeks) (SD) | n (hands) | Mean age (SD) | Mean symptom duration (weeks) (SD) | ||||
Roh et al., 201933 | Single 2-mL injection that contained 1 mL of lidocaine (10 mg/mL) and 1 mL of triamcinolone acetonide (20 mg/mL) | Out-of-plane ulnar approach | 51 | 54 (35–64) (range) | 15 (3–84) (range) | 51 | 55 (37–66) (range) | 14 (3–60) (range) | BCTQ (SSS, FSS) | 24 |
Rayegani et al., 201934 | 1 mL of triamcinolone 40 mg plus to 1 mL of lidocaine 2% | In-plane ulnar approach | 26 | 54.39 (9.3) | N/A | 27 | 54.39 (9.3) | N/A | BCTQ (SSS, FSS) and electrodiagnostic findings (SNAP, CMAP) | 10 |
Vahdatpour et al., 201932 | Methylprednisolone acetate 40 mg without local anesthetics | In-plane ulnar approach | 29 | 48.14 (9.41) | N/A | 23 | 47.61 (8.30) | N/A | BCTQ (SSS, FSS) and electrodiagnostic findings (SNAP, CMAP) | 12 |
Chen et al., 201831 | Betamethasone 1 ml (Betamethasone 1 ml /amp, 1 ml contains betamethasone dipropionate 5 mg and betamethasone disodium phosphate 2 mg) | Out-of-plane ulnar approach | 22 | 51.09 (10.09) | 70.55 (70.61) | 17 | 51.12 (8.19) | 65.12 (63.03) | BCTQ (SSS, FSS) and electrodiagnostic findings (SNAP, SNCV, DML, CMAP) | 72 |
Karaahmet et al., 201730 | 1 mL of betamethasone sodium phosphate (2.63 mg)/betamethasone dipropionate (6.43 mg) | In-plane ulnar approach | 15 | 59.4 (12.4) | 28.5 (30.6) Days | 16 | 61.5 (10.3) | 38.5 (40.4) Days | BCTQ (SSS, FSS) and electrodiagnostic findings (SNAP, SNCV, DML, CMAP) | 4 |
Eslamian et al., 201729 | 40 mg of methylprednisolone without local anesthetic | In-plane ulnar approach | 30 | 54.52 (2.05) | N/A | 30 | 49.33 (1.82) | N/A | BCTQ (SSS, FSS) and electrodiagnostic findings (SNAP, SNCV, DML, CMAP) | 12 |
Lee et al., 201428 | 1 mL of 40 mg/mL triamcinolone and 1 mL of 1% lidocaine | In-plane ulnar approach | 26 | 55.2 (13.2) | 8.9 (2.2) | 15 | 50.3 (9.6) | 7.6 (2.9) | BCTQ (SSS, FSS) and electrodiagnostic findings (DML, CMAP, DSL, SNAP) | 12 |
Out-of-plane ulnar approach | 24 | 52.6 (11.60 | 9.4 (3.6) | |||||||
Ustün et al., 201327 | 40 mg of methylprednisolone | Out-of-plane ulnar approach | 23 | 45.96 (10.49) | 16.78 (10.65) | 23 | 42.71 (11.38) | 10.19 (10.19) | BCTQ (SSS, FSS) | 12 |
